AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A ~~solid oral dosage form pharmaceutical for the treatment of~~capsule



~~dysuria~~, which comprises~~,~~ (1) a granular material containing a) as an active ingredient, an indoline compound ~~having an α_1-adrenoceptor blocking activity and~~ represented by the formula:



~~a prodrug thereof, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof,~~ b) D-mannitol and c) partially pregelatinized starch; and (2) d) a lubricant selected from magnesium stearate, calcium stearate or talc, and e) sodium lauryl sulfate, wherein 85% dissolution time is not more than 60 minutes in a dissolution test according to method 2 (paddle

method) of Japanese pharmacopoeia in a condition using water as a test medium and a paddle speed of 50rpm.

Claims 2. - 7. (canceled).

8. (currently amended): The ~~pharmaceutical~~ capsule according to claim 1~~7~~, wherein the lubricant is magnesium stearate.

9. (currently amended): The ~~pharmaceutical~~ capsule according to claim 8, which ~~further~~ comprises 0.1 to 2 parts of sodium lauryl sulfate based on 1 part of magnesium stearate.

Claim 10. (canceled)

11. (currently amended): The ~~pharmaceutical~~ capsule according to claim ~~10~~1, wherein the capsule is a light-shielding capsule.

12. (currently amended): The ~~pharmaceutical~~ capsule according to claim 11, wherein the light- shielding capsule ~~is a~~comprises a capsule shell containing titanium oxide.

Claims 13. - 26. (canceled).

27. (new): The capsule according to claim 8, which comprises 0.5 to 1 part of sodium lauryl sulfate based on 1 part of magnesium stearate.